Nav: Home

Stereochemistry: Self-amplifying selectivity

December 05, 2016

Ludwig-Maximilians-Universitaet (LMU) in Munich chemist Oliver Trapp has designed and synthesized a catalyst which flexibly molds the handedness of the reaction products with which it interacts.

Many chemical compounds contain so-called chiral centers to which functional groups can be attached in either of two orientations. This gives rise to two different forms of the product which are mirror images of one another: Their spatial conformations are related to each other in the same way as right and left hands. Moreover, such configurational pairs - generally referred to as enantiomers - may exhibit different properties. For this reason, synthetic chemists are often faced with the problem of ensuring that the final product has the correct enantiomeric form. Oliver Trapp (Professor of Organic Chemistry at LMU since September 2016) and Golo Storch (a member of his previous research group at Heidelberg University, and currently at Yale University) now report the development of a catalyst that dynamically adapts to the stereochemistry of the compounds with which it interacts, and can progressively select for the desired enantiomer. The work is described in a paper which has just appeared in the journal Nature Chemistry.

Their system is based on a pair of molecular backbones that are known to interact with one another with enantiomeric selectivity. One of these serves as the carrier of the desired product while the other is equipped with a metal catalyst and flexible binding sites that recognize the product. The catalyst interacts transiently and repeatedly with the products of its own action, and can swiftly adjust the configuration of its binding sites. "We ourselves were surprised at how rapidly the catalyst adapts," Trapp says. These interactions effectively modify the structure of the catalyst in such a way that its stereoselectivity is enhanced. Once the catalyst has recognized the desired enantiomer, its selective efficiency improves with every further catalytic cycle. The final result of this self-amplifying action is that the end-products all have the same chiral structure.

This dynamic adaptability is of great interest in the context of the drug industry's never-ending search for biologically active compounds. Not only that, it may throw new light on how stereoselective chemical reactions operate in biological systems, where one normally finds only one chiral form of any given compound. "The world in which we live is monochiral," says Trapp. "Researchers have not yet found a convincing explanation for this. But it is conceivable that the functional principle of supermolecular interaction which we have exploited was also crucial for the origin of life."

Ludwig-Maximilians-Universität München

Related Binding Sites Articles:

Research into Parkinson's disease: Binding-protein prevents fibril proliferation
Several neurodegenerative diseases such as Parkinson's are closely linked to the aggregation of a specific protein, α-synuclein.
NTU Singapore scientists uncover binding secret behind protein 'superglue'
Scientists from Nanyang Technological University, Singapore have pinpointed how a special class of plant-derived enzymes, known as peptide ligases, work to join proteins together -- an important process in the development of drugs, for example in specifically attaching a chemotherapy drug to an antibody that recognizes tumor markers to target cancer cells.
Diving into the details: A lipid-binding pocket is a target for new cancer therapies
Cell growth is tightly controlled; however, cancer cells overcome the normal growth controls and proliferate uncontrollably.
Binding affinities of perfluoroalkyl substances to Baikal seal PPARα
The present study assessed the binding affinities of perfluoroalkyl substances (PFASs) to the Baikal seal peroxisome proliferator-activated receptor α (PPARα) and compared them with those of human PPARα.
Researchers optimize aptamer with enhanced myelin-binding properties for MS treatment
A new study has demonstrated the enhanced ability of an optimized 20-nucleotide derivative of a larger DNA aptamer to bind myelin in a mouse model of multiple sclerosis.
More Binding Sites News and Binding Sites Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...